Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Karolinska Development AB ( (SE:KDEV) ) is now available.
Karolinska Development’s portfolio company, Modus Therapeutics, has received regulatory approval in Italy to commence the second part of its phase 2 study for sevuparin as a treatment for chronic kidney disease with anemia. This milestone aligns with the company’s development timeline and signifies progress in the clinical development of sevuparin, potentially impacting the company’s market positioning and stakeholder interests positively.
More about Karolinska Development AB
Karolinska Development AB is a Nordic life sciences investment company focused on identifying and investing in breakthrough medical innovations in the Nordic region. The company supports the creation and growth of companies that develop these innovations into commercial products aimed at improving patient lives and providing attractive returns to shareholders. With access to top-tier medical innovations from institutions like the Karolinska Institutet, Karolinska Development works with experienced management teams and international investors to maximize success.
Average Trading Volume: 286,695
Current Market Cap: SEK234.5M
Learn more about KDEV stock on TipRanks’ Stock Analysis page.